Oncolytics Biotech Inc. reached agreement with the FDA on the design of a Phase III trial of Reolysin in head and neck cancer, marking the first such agreement for an intravenously administered oncolytic virus. (BioWorld Today)

Threshold Pharmaceuticals Inc. plans to raise about $35 million through the sale of stock and warrants, money that will help advance its cancer drug pipeline and extend its cash well into 2011. (BioWorld Today)

In relatively short order, Plexxikon Inc. has moved its melanoma product from a Phase I study to pivotal trials, the first of which has begun enrolling patients. (BioWorld Today)